IM-250 (Adibelivir, oral)

About Innovative Molecules

Innovative Molecules is a private, clinical-stage biotech focused on developing novel antiviral therapies for herpes simplex virus (HSV) infections. Its lead program, IM-250 (adibelivir), an oral helicase-primase inhibitor, has completed Phase 1 and advanced to Phase 2 trials, demonstrating a targeted mechanism to control recurrent disease and latent virus. The company has secured significant Series A funding and established a strategic partnership with Alfasigma for a parenteral formulation, positioning it to address a substantial unmet medical need in a market dominated by older, less effective nucleoside analogues.

Therapeutic Areas